Literature DB >> 26216565

Developmental outcomes of 3,4-methylenedioxymethamphetamine (ecstasy)-exposed infants in the UK.

Lynn T Singer1, Derek G Moore2, Meeyoung O Min1, Julia Goodwin2, John J D Turner2, Sarah Fulton1, Andrew C Parrott3.   

Abstract

OBJECTIVE: This paper aims to review findings from a longitudinal study of prenatal methylenedioxymethamphetamine (MDMA, "ecstasy") on infant development.
METHODS: In a prospective, longitudinal cohort design, we followed 28 MDMA-exposed and 68 non-MDMA-exposed infants from birth to 2 years of age. Women recruited voluntarily into a study of recreational drug use during pregnancy were interviewed to obtain type, frequency, and amount of recreational drug use. Their children were followed for a 2-year period after birth. A large number of drug and environmental covariates were controlled. Infants were seen at 1, 4, 12, 18, and 24 months using standardized normative tests of mental and motor development.
RESULTS: There were no differences between MDMA-exposed and non-MDMA-exposed infants at birth except that MDMA-exposed infants were more likely to be male. Motor delays were evident in MDMA infants at each age and amount of MDMA exposure predicted motor deficits at 12 months in a dose-dependent fashion.
CONCLUSIONS: Prenatal MDMA exposure is related to fine and gross motor delays in the first 2 years of life. Follow-up studies are needed to determine long-term effects.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  MDMA; ecstasy; infant development; methylenedioxymethamphetamine; motor; prenatal

Mesh:

Substances:

Year:  2015        PMID: 26216565      PMCID: PMC5107979          DOI: 10.1002/hup.2459

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  30 in total

Review 1.  A review of the clinical pharmacology of methamphetamine.

Authors:  Christopher C Cruickshank; Kyle R Dyer
Journal:  Addiction       Date:  2009-04-29       Impact factor: 6.526

Review 2.  A developmental comparison of the neurobehavioral effects of ecstasy (MDMA).

Authors:  Brian J Piper
Journal:  Neurotoxicol Teratol       Date:  2006-10-20       Impact factor: 3.763

3.  Prenatal cocaine exposure: drug and environmental effects at 9 years.

Authors:  Lynn T Singer; Suchitra Nelson; Elizabeth Short; Meeyoung O Min; Barbara Lewis; Sandra Russ; Sonia Minnes
Journal:  J Pediatr       Date:  2008-03-06       Impact factor: 4.406

4.  Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy.

Authors:  Lynn T Singer; Derek G Moore; Sarah Fulton; Julia Goodwin; John J D Turner; Meeyoung O Min; Andrew C Parrott
Journal:  Neurotoxicol Teratol       Date:  2012-03-03       Impact factor: 3.763

5.  Psychiatric profiles of mothers who take Ecstasy/MDMA during pregnancy: reduced depression 1 year after giving birth and quitting Ecstasy.

Authors:  John J D Turner; Andrew C Parrott; Julia Goodwin; Derek G Moore; Sarah Fulton; Meeyoung O Min; Lynn T Singer
Journal:  J Psychopharmacol       Date:  2013-12-10       Impact factor: 4.153

Review 6.  The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

Authors:  A Richard Green; Annis O Mechan; J Martin Elliott; Esther O'Shea; M Isabel Colado
Journal:  Pharmacol Rev       Date:  2003-07-17       Impact factor: 25.468

7.  During pregnancy, recreational drug-using women stop taking ecstasy (3,4-methylenedioxy-N-methylamphetamine) and reduce alcohol consumption, but continue to smoke tobacco and cannabis: initial findings from the Development and Infancy Study.

Authors:  Derek G Moore; John D Turner; Andrew C Parrott; Julia E Goodwin; Sarah E Fulton; Meeyoung O Min; Helen C Fox; Fleur M B Braddick; Emma L Axelsson; Stephanie Lynch; Helena Ribeiro; Caroline J Frostick; Lynn T Singer
Journal:  J Psychopharmacol       Date:  2009-11-25       Impact factor: 4.153

Review 8.  Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues.

Authors:  Fabrizio Schifano; Antonio Albanese; Suzanne Fergus; Jackie L Stair; Paolo Deluca; Ornella Corazza; Zoe Davey; John Corkery; Holger Siemann; Norbert Scherbaum; Magi' Farre'; Marta Torrens; Zsolt Demetrovics; A Hamid Ghodse
Journal:  Psychopharmacology (Berl)       Date:  2010-11-12       Impact factor: 4.530

9.  A cohort study of the association between secondary sex ratio and parental exposure to polybrominated biphenyl (PBB) and polychlorinated biphenyl (PCB).

Authors:  Metrecia L Terrell; Alissa K Berzen; Chanley M Small; Lorraine L Cameron; Julie J Wirth; Michele Marcus
Journal:  Environ Health       Date:  2009-08-15       Impact factor: 5.984

Review 10.  MDMA and heightened cortisol: a neurohormonal perspective on the pregnancy outcomes of mothers used 'Ecstasy' during pregnancy.

Authors:  Andrew C Parrott; Derek G Moore; John J D Turner; Julia Goodwin; Meeyoung O Min; Lynn T Singer
Journal:  Hum Psychopharmacol       Date:  2014-01       Impact factor: 2.130

View more
  2 in total

Review 1.  Stimulant Use in Pregnancy: An Under-recognized Epidemic Among Pregnant Women.

Authors:  Marcela C Smid; Torri D Metz; Adam J Gordon
Journal:  Clin Obstet Gynecol       Date:  2019-03       Impact factor: 2.190

2.  Motor delays in MDMA (ecstasy) exposed infants persist to 2 years.

Authors:  Lynn T Singer; Derek G Moore; Meeyoung O Min; Julia Goodwin; John J D Turner; Sarah Fulton; Andrew C Parrott
Journal:  Neurotoxicol Teratol       Date:  2016-01-21       Impact factor: 3.763

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.